ACE2 and obesity disorder: Although the interference of comorbidities and medications with ACE2 expression is controversial [68,69,70,71,72,73], in the present study, consistent differences in the protein levels of the SARS-CoV-2 mediators were observed between groups with or without obesity, despite comparable comorbidity profiles and similar patterns of medication use.